Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ho-Sup Lee

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Cell Reports|August 20, 2023
IL-2 can signal via chemokine receptors to promote regulatory T cells' suppressive functionHao Sun, Ho-Sup Lee, Sarah Hyun-Ji Kim, et al.
Annals of Hematology|April 6, 2018
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysisJung Yong Hong, Dok Hyun Yoon, Cheolwon Suh, et al.
Blood Research|April 17, 2013
Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in KoreaSunhyun Ahn, Joon Seong Park, Seong Hyun Jeong, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 18, 2011
Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from KoreaHo Sup Lee, Lee Chun Park, Eun Mi Lee, et al.
Cancer Research and Treatment|July 22, 2014
Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label StudySeong Hoon Shin, Ho Sup Lee, Yang Soo Kim, et al.
British Journal of Haematology|November 28, 2025
A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803)Sung-Hoon Jung, Dajung Kim, Je-Jung Lee, et al.
Scientific Reports|July 17, 2020
Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab eraGa-Young Song, Sang Eun Yoon, Seok Jin Kim, et al.
Oncotarget|November 8, 2017
Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working PartyDa Jung Kim, Ho Sup Lee, Joon-Ho Moon, et al.
Annals of Hematology|April 8, 2016
The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of KoreaHo Sup Lee, Chang-Ki Min, Je-Jung Lee, et al.
Annals of Hematology|December 20, 2019
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma reportJae-Cheol Jo, Seok Jin Kim, Ho Sup Lee, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Cell Reports|August 20, 2023
IL-2 can signal via chemokine receptors to promote regulatory T cells' suppressive functionHao Sun, Ho-Sup Lee, Sarah Hyun-Ji Kim, et al.
Annals of Hematology|April 6, 2018
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysisJung Yong Hong, Dok Hyun Yoon, Cheolwon Suh, et al.
Blood Research|April 17, 2013
Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in KoreaSunhyun Ahn, Joon Seong Park, Seong Hyun Jeong, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 18, 2011
Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from KoreaHo Sup Lee, Lee Chun Park, Eun Mi Lee, et al.
Cancer Research and Treatment|July 22, 2014
Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label StudySeong Hoon Shin, Ho Sup Lee, Yang Soo Kim, et al.
British Journal of Haematology|November 28, 2025
A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R-VRD) in patients with Waldenström's macroglobulinaemia (KMM1803)Sung-Hoon Jung, Dajung Kim, Je-Jung Lee, et al.
Scientific Reports|July 17, 2020
Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab eraGa-Young Song, Sang Eun Yoon, Seok Jin Kim, et al.
Oncotarget|November 8, 2017
Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working PartyDa Jung Kim, Ho Sup Lee, Joon-Ho Moon, et al.
Annals of Hematology|April 8, 2016
The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of KoreaHo Sup Lee, Chang-Ki Min, Je-Jung Lee, et al.
Annals of Hematology|December 20, 2019
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma reportJae-Cheol Jo, Seok Jin Kim, Ho Sup Lee, et al.
Pageof 14